HIV treatment bulletin

RSS Atom • ISSN 1472-4683 • Subscribe • About

2003

Previous page • Next page

• Postnatal transmission of HIV to breastfed infants following short course ZDV regimen PMTCT and maternal health - 1 October 2003

• Subtype differences in mother to child transmission PMTCT and maternal health - 1 October 2003

• Influence of mothers’ health and survival on children’s survival PMTCT and maternal health - 1 October 2003

• Higher than currently recommended NVP dose shows greater efficacy in HIV-infected children Paediatric care - 1 October 2003

• Time on anti-HIV therapy is a protective factor for liver fibrosis in HIV-HCV coinfected patients Hepatitis coinfection - 1 October 2003

• HIV-HCV co-infected patients have poorer response to HCV therapy Hepatitis coinfection - 1 October 2003

• CDC study shows rifampin/pyrazinamide therapy can cause severe liver damage TB coinfection - 1 October 2003

• Impact of the HIV epidemic in sub-Saharan Africa on the pattern of HIV in the UK Other news - 1 October 2003

• Dutch pharmacies sell medical marijuana Other news - 1 October 2003

• Conferences and guidelines On the web - 1 October 2003

• Medscape articles On the web - 1 October 2003

• Journal articles On the web - 1 October 2003

• HIV inSite: HIV Knowledge Database On the web - 1 October 2003

• Online medical lectures On the web - 1 October 2003

• Other websites On the web - 1 October 2003

• Volume 4 Number 8 October 2003 PDF PDFs - 1 October 2003

• Volume 4 Number 7 August/September 2003 Editorial - 1 September 2003

• EMEA public statement on early virologic non-response in patients with HIV infection treated with tenofovir in combination with lamivudine and abacavir Treatment alerts - 1 September 2003

• XII International HIV Drug Resistance Workshop, Los Cabos, Mexico, 10-14 June 2003 Conference reports - Resistance - Conference index - Intl Drug Resistance Workshop 12 Mexico 2003 - 1 September 2003

• Transmission of drug resistance – at 11% in Europe and 17% in the UK Conference reports - Resistance - Transmission and prevention - Intl Drug Resistance Workshop 12 Mexico 2003 - 1 September 2003

• HIV coinfection, reinfection and superinfection Conference reports - Hepatitis coinfection - Resistance - Transmission and prevention - Intl Drug Resistance Workshop 12 Mexico 2003 - 1 September 2003

• Single-dose nevirapine resistance in over 75% of mothers Conference reports - PMTCT and maternal health - Resistance - Women's health - Intl Drug Resistance Workshop 12 Mexico 2003 - 1 September 2003

• Transmission of drug resistant virus does not revert to wild-type and does not appear ‘less fit’ Conference reports - Resistance - Intl Drug Resistance Workshop 12 Mexico 2003 - 1 September 2003

• Standard genotype assays may miss 75% of mutations when present in less than 35% of plasma sample Conference reports - Resistance - Intl Drug Resistance Workshop 12 Mexico 2003 - 1 September 2003

• Low-level resistance and minority populations: cross resistance between nevirapine and efavirenz occurs even in the absence of genotypic mutations found using population sequencing Conference reports - Resistance - Intl Drug Resistance Workshop 12 Mexico 2003 - 1 September 2003

• Persistent effect of d4T and 3TC, but not NNRTIs in the presence of associated genotypic mutations Conference reports - Resistance - Intl Drug Resistance Workshop 12 Mexico 2003 - 1 September 2003

• Replicative capacity results complicated by minority wild-type virus Conference reports - Resistance - Virology - Intl Drug Resistance Workshop 12 Mexico 2003 - 1 September 2003

• Tenofovir, resistance and K65R and concomitant nucleosides Antiretrovirals - Conference reports - Resistance - 1 September 2003

• Response to STI is determined by virus rather than immunological response Conference reports - Resistance - Intl Drug Resistance Workshop 12 Mexico 2003 - 1 September 2003

• Why resistance rarely develops with viral suppression <50 copies/mL Conference reports - Resistance - Intl Drug Resistance Workshop 12 Mexico 2003 - 1 September 2003

• Long-term persistence of distinct mutations in genital tract Conference reports - Resistance - Women's health - Intl Drug Resistance Workshop 12 Mexico 2003 - 1 September 2003

• 5th International Workshop on Adverse Drug Reactions and Lipodystrophy, 8-11 July 2003, Paris Conference reports - Lipodystrophy and metabolic complications - Conference index - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003

• Underlying mechanisms: adipocytes and cytokines Basic science and immunology - Conference reports - Lipodystrophy and metabolic complications - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003

• More mitochondrial DNA depletion Conference reports - Lipodystrophy and metabolic complications - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003

• IMT and cardiovascular risk Conference reports - Lipodystrophy and metabolic complications - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003

• Reduced bone mineral density in HIV-positive women Conference reports - Lipodystrophy and metabolic complications - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003

• Rosiglitazone with insulin resistance Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003

• Additional benefits of exercise with metformin Conference reports - Lipodystrophy and metabolic complications - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003

• Mitochondrial toxicity with AZT and d4T – and benefits of switch to abacavir Antiretrovirals - Conference reports - Lipodystrophy and metabolic complications - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003

• Facial fat loss – measuring and treatment Conference reports - Lipodystrophy and metabolic complications - Treatment access - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003

• Uridine treatment for mitochondrial toxicity Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003

• Breast enlargement in men and testosterone treatment Conference reports - Lipodystrophy and metabolic complications - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003

• Severe efavirenz psychotic events Conference reports - Side effects - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003

• Treatment interruption: a real choice Conference reports - Lipodystrophy and metabolic complications - Treatment strategies - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003

• 2nd IAS Conference on HIV Pathogenesis and Treatment, 13-16 July 2003, Paris Conference reports - Conference index - IAS 2 Paris 2003 - 1 September 2003

• Nevirapine and MTCT: the single-dose backlash Antiretrovirals - Conference reports - PMTCT and maternal health - Paediatric care - Women's health - IAS 2 Paris 2003 - 1 September 2003

• Triple nucleoside combinations fail patients again Antiretrovirals - Conference reports - IAS 2 Paris 2003 - 1 September 2003

• Nucleoside-sparing regimens Antiretrovirals - Conference reports - Treatment strategies - IAS 2 Paris 2003 - 1 September 2003

• Dual boosted PIs in salvage therapy Antiretrovirals - Conference reports - IAS 2 Paris 2003 - 1 September 2003

• BMS reports on atazanavir efficacy and safety in treatment experienced patients Antiretrovirals - Conference reports - IAS 2 Paris 2003 - 1 September 2003

• Unsupervised treatment interruptions are associated with increased risk of AIDS or death Antiretrovirals - Conference reports - IAS 2 Paris 2003 - 1 September 2003

• Uridine as a potential treatment for NRTI related mitochondrial toxicity Conference reports - PK and drug interactions - Side effects - Lipodystrophy Workshop (IWADRW) 5 Paris 2003 - 1 September 2003

• Long term exposure to nucleoside analogues and peripheral nerve function Conference reports - Side effects - IAS 2 Paris 2003 - 1 September 2003

• Step-wise intervention eases diarrhoea linked to PI nelfinavir (Viracept) therapy Antiretrovirals - Conference reports - Side effects - IAS 2 Paris 2003 - 1 September 2003

• First results from ESPRIT study: CD4 response to IL-2 is associated with higher nadir and baseline CD4 and younger age Basic science and immunology - Conference reports - 1 September 2003

• Lessons learned from early HAART in acute HIV infection Antiretrovirals - Conference reports - Treatment strategies - 1 September 2003

• CD4 cell reconstitution is significantly slower in older patients Antiretrovirals - Basic science and immunology - Conference reports - IAS 2 Paris 2003 - 1 September 2003

• Pharmacology studies at the 2nd IAS conference Antiretrovirals - Conference reports - PK and drug interactions - PMTCT and maternal health - IAS 2 Paris 2003 - 1 September 2003

• Studies highlight problems of rectal disease in HIV-positive patients Conference reports - Opportunistic infections and complications - IAS 2 Paris 2003 - 1 September 2003

• Appointment of industry executive to supervise US AIDS initiative provokes criticism Treatment access - 1 September 2003

• T-20 launched in UK Antiretrovirals - 1 September 2003

• US guidelines updated Guidelines - 1 September 2003

• US approval of FTC (emtricitabine) Antiretrovirals - 1 September 2003

• Resistance summary of new PIs: atazanavir and tipranavir Resistance - 1 September 2003

• Bone mineral metabolism and HIV-infection Side effects - 1 September 2003

• Protease inhibitors and Kaposi’s sarcoma (KS): KS relapse seen after switch from PI to NNRTI Opportunistic infections and complications - 1 September 2003

• UK highest rate of new infections at over 5,000 cases Other news - 1 September 2003

• Medicines Control Agency slated by Commons committee Other news - 1 September 2003

• Conference reports and abstracts On the web - 1 September 2003

• Medscape articles On the web - 1 September 2003

• Newletters and reports On the web - 1 September 2003

• Volume 4 Number 7 August/September 2003 PDF PDFs - 1 September 2003

• Volume 4 Number 6 July 2003 Editorial - 1 July 2003

• Activist anger over US ‘ambush’ of the Global Fund Treatment access - 1 July 2003

• $15 billion AIDS bill signed, but full funding shaky Treatment access - 1 July 2003

• New GAA report: US and G8 must act fast to rescue Global Fund Treatment access - 1 July 2003

• World Health Assembly approves resolution supporting public health considerations in drug policy Treatment access - 1 July 2003

• WHO Assembly analysis Treatment access - 1 July 2003

• Bill Gates to give $1 million to Brazil’s AIDS programme Treatment access - 1 July 2003

• Adherence is not a barrier to successful antiretroviral therapy in South Africa Treatment access - 1 July 2003

• T-20 approved in Europe Antiretrovirals - 1 July 2003

• Tenofovir European licence extended to include first-line therapy Antiretrovirals - 1 July 2003

• FDA approves atazanavir in US – a once daily protease inhibitor Antiretrovirals - 1 July 2003

• Atanazavir and saquinavir in salvage therapy: reduced effect on lipids shown in pilot study Antiretrovirals - 1 July 2003

• Major change to OPTIMA salvage therapy study in the UK Antiretrovirals - 1 July 2003

• Is stress associated with CIN progression in HIV-positive women? Cancer and HIV - Women's health - 1 July 2003

• FDA says some follow-up drug studies are never started Side effects - 1 July 2003

• Lamotrigine shows some benefit for HIV-associated painful sensory neuropathies Side effects - 1 July 2003

• HIV and heart disease: D:A:D prevalence rates show importance of accessing CVD risk in HIV patients Lipodystrophy and metabolic complications - 1 July 2003

• HAART increases body fat at first; both d4T and AZT lead to subsequent fat loss Lipodystrophy and metabolic complications - 1 July 2003

• Lipoatrophy improved by switching from d4T to abacavir Lipodystrophy and metabolic complications - 1 July 2003

• T cell activation is associated with decreased CD4+ T cell gains during ARV therapy Basic science and immunology - 1 July 2003

• Structured treatment interruptions trial shows no benefit Basic science and immunology - 1 July 2003

• New antibiotic appears effective against MDR-TB TB coinfection - 1 July 2003

• Tobacco use increases risk for pulmonary diseases and weakens response to therapy in patients on HAART Opportunistic infections and complications - 1 July 2003

• EBV levels in HIV-positive patients are not reduced by HAART Cancer and HIV - Opportunistic infections and complications - 1 July 2003

• The efficacy of fluconazole (Diflucan) 600 mg/day versus itraconazole (Sporanox) 600 mg/day for treatment of cryptococcal meningitis in AIDS patients Opportunistic infections and complications - 1 July 2003

• Risk factors for paediatric HIV malignancies Cancer and HIV - Paediatric care - 1 July 2003

• TREC analysis shows little thymic damage in HIV-positive adolescents Paediatric care - 1 July 2003

• Metabolic abnormalities in protease inhibitor-treated and protease naïve children Lipodystrophy and metabolic complications - Paediatric care - 1 July 2003

Previous page • Next page